THROMBUS IN TRANSIT ACROSS THE PATENT FORAMEN OVALE  by Biglane, John B. et al.
FIT Clinical Decision Making
A664
JACC March 17, 2015
Volume 65, Issue 10S
tHrOMBuS in tranSit acrOSS tHe patent FOraMen OVale
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: FIT Clinical Decision Making: Structural Heart Disease and Pulmonary Hypertension
Abstract Category: Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease
Presentation Number: 1142-170
Authors: John B. Biglane, Kristen C. Crawford, John Saxon, Cameron Guild, Thomas Skelton, Giorgio Aru, Myrna Alexander Nickens, 
Michael Hall, University of Mississippi Medical Center, Jackson, MS, USA
Background:  Patent foramen ovale (PFO) is common occurring in approximately 10-35% of patients. Paradoxical emboli are less so, but 
we presume that a paradoxical embolism causes cryptogenic stroke in patients with a PFO. It is rare to find a thrombus in transit.
Case Description: 62 year old male presented with a 2 week history of progressively worsening shortness of breath and bilateral lower 
extremity edema. He was tachycardic, tachypneic and mildly hypoxemic. A CT scan confirmed extensive bilateral pulmonary emboli with 
substantial thrombus burden. Venous Dopplers demonstrated an acute deep vein thrombosis in the right lower extremity. Both transthoracic 
and transesophageal echocardiography showed a large thrombus in transit trapped in the PFO measuring approximately 3.7cm.
decision Making:  PFO with thrombus in transit presents a complicated therapeutic dilemma. After comprehensive discussion with the 
patient and cardiothoracic surgery, and due to the patient’s hemodynamic stability with minimal oxygen requirement, we started a heparin 
infusion instead of proceeding with embolectomy or thrombolytic therapy. Repeat echo demonstrated resolution of the thrombus within 5 
days without evidence of paradoxical embolism.
conclusion:  Scant literature is available on the best treatment in this setting. A case series shows heparin to be equivalent to other 
treatments. This is consistent with our previous experience treating patients with similar presentations successfully with heparin infusions.
 
